organization · Reporting owner
Bayer Global Investments B.V.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | 10% owner | January 05, 2018 | January 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date January 05, 2018 · Filed January 30, 2018
Jointly reported with BAYER AKTIENGESELLSCHAFT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy subsidiary | 5,632,802 |
Reported balance
After 2018-01-05 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2018-01-05 · Purchase · Acquired 527,472 · Balance 5,632,802 F1: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner. |
| Common SharesSEC Table I · non-derivative | IndirectBy subsidiary | 75,945 |
Reported balance
Holding disclosure · report date 2018-01-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 75,945 F2: Reflects shares of CRISR received by a subsidiary of Bayer AG as a pro rata distribution from a limited partnership. Bayer AG is the 100% Indirect Owner through subsidiaries of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner.
F2: Reflects shares of CRISR received by a subsidiary of Bayer AG as a pro rata distribution from a limited partnership. Bayer AG is the 100% Indirect Owner through subsidiaries of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2018 Filed Jan 30, 2018 14:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 527,472 | $22.75 | $11,999,988.00 |
DisclosureSEC source: 0000029905-18-000006 · edgar.xml · nonDerivative · entry 1 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer Global Investments B.V. · CIK 0001685417 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 5,632,802 F1 · ownership.nature: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.